Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2023)
15 slides from Idt Australia's shareholder meeting presentation, Nov 23, 2023
Slide 1: IDT Australia Annual General Meeting 2023
1 IDT Australia ANNUAL GENERAL MEETING 2023
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices 2 This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does n
Slide 3: Year of Achievements
YEAR OF ACHIEVEMENTS 3 S T R O N G S T A R T T O F Y 2 4 Return to Growth Strengthen Posted 5th consecutive quarter of rising revenues Balance Sheet Build a strong pipeline of sales opportunities Unlock New Successfully completed a Increase strategic value $7M capital raise to fund Opportuni
Slide 4: Growth in Key Verticals
GROWTH IN KEY VERTICALS 4 F Y 2 3 R E S U L T S H I G H L I G H T S Revenue from Key Business Verticals up 24% YoY Strategic pivot to build three key verticals already yielding positive results $14 Millions FY23 revenue from these verticals jumped 24% YoY $12 to $6.4M and is a more accurate refl
Slide 5: Growth Momentum into FY24
GROWTH MOMENTUM INTO FY24 5 I M P R O V I N G R E S U L T S Increasing Sales Accelerating Demand Strong Outlook Strong start to FY24 with 5th Momentum accelerating into Sales pipeline of opportunities consecutive rise in unaudited 2QFY24 continues to expand significantly revenue in 1QFY24 Wo
Slide 6: Core Business Pillars
CORE BUSINESS PILLARS 6 I D T A U S T R A L I A ’ S B U S I N E S S D I V I S I O N S Active Pharmaceutical Ingredient (API) Finished Dosage Forms (FDFs) The active component which produces the required effect in drugs A drug product in the final form that can be administered to a patient Specialty
Slide 7: Large Addressable Markets
LARGE ADDRESSABLE MARKETS 7 L E V E R A G E D T O M U L T I P L E L U C R A T I V E O P P O R T U N I T I E S Advanced Therapies Specialty Orals API Manufacturing Aseptic Fill & Finish Medicinal Cannabis & (ADC & mRNA) Psychedelics API Production • TAM: Global market forecast to • TAM: Global market
Slide 8: Advanced Therapies
ADVANCED THERAPIES 8 G R O W I N G D E M A N D & L I M I T E D S U P P L Y Achieved revenue of $200K in FY23 Secured sterile license extension in and further $187K* in 1QFY24 with April 2023 from TGA more growth expected IDT’s Aseptic Sterile Processing (ASP) facility is one of only a few in Austral
Slide 9: Replacing Traditional Chemo
REPLACING TRADITIONAL CHEMO 9 > U S $ 1 4 0 B N O P P : M O V I N G F R O M T R A D I T I O N A L T O “ S M A R T ” C H E M O 1 "Smart chemotherapy" is the idea of using an antibody to act as a guidance system to find a cancer, and attaching chemotherapy molecules to the antibody to destroy the canc
Slide 10: Specialty Orals
SPECIALTY ORALS 10 K E Y D R I V E R O F N E A R - T E R M G R O W T H Growing revenue – FY23: +13% YoY to $4.6M & 1QFY24: +200% pcp to >$1.4M* IDT Australia has the licensure, Leveraged to rapid growth in mental illness treatment market capabilities and facilities to manufacture a range of medicina
Slide 11: Specialty Orals
SPECIALTY ORALS 11 A D D I T I O N A L G R O W T H O P P O R T U N I T Y I N P S Y C H E D E L I C S The Therapeutic Goods Administration (TGA) is permitting the prescription of MDMA for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression from 1 J
Slide 12: API Manufacturing
API MANUFACTURING 12 L A R G E S T E S T A B L I S H E D L E A D E R Revenue jumped 48% YoY to $1.7M in FY23 and up Deep experience in high potent small 10X in 1QFY24 vs. pcp to $1.2M* molecule R&D, process design, scale and validation. The API vertical represented 24% of Group revenue in • Active P
Slide 13: Outlook
OUTLOOK 13 G R O W T H D R I V E R S I N F Y 2 4 A N D B E Y O N D Positive Early Results Growth Drivers Signs of turnaround success with quarterly Leveraged to fast growing segments: ADC, revenue increasing significantly mental illness Organic Tailwinds Multiple Opportunities Forecast 15% CAGR (202
Slide 14: IDT Australia
14 IDT Australia
Slide 15: Glossary
15 Glossary ADC Antibody Drug Conjugate MDMA Methylene-dioxy-meth-amphetamine API Active Pharmaceutical Ingredient ODC Office of Drug Control ASP Aseptic Sterile Processing PTSD Post Traumatic Stress Disorder CDMO Contract Development & Manufacturing Organisation SAS Special Access Scheme FDA U.S. F